SMIM20 and depressive symptom measurement: A recent publication studied the effects of the long-term olanzapine treatment on both NUCB2/nesfatin-1 and phoenixin/SMIM20 mRNA expression in rodent brains and showed an increased expression of phoenixin/SMIM20 with an unaltered NUCB2/nesfatin-1 level, falling in line with the anxiolytic and antidepressant properties of olanzapine, as well as supporting the notion of a counterbalancing role of phoenixin and nesfatin in depression/anxiety [98].